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Evaluation of the biomarker candidate 
MFAP4 for non-invasive assessment of hepatic 
fibrosis in hepatitis C patients
Thilo Bracht1*†, Christian Mölleken2†, Maike Ahrens1, Gereon Poschmann3, Anders Schlosser4, 
Martin Eisenacher1, Kai Stühler3, Helmut E. Meyer1, Wolff H. Schmiegel2, Uffe Holmskov4, Grith L. Sorensen4† 
and Barbara Sitek1†
Abstract 
Background: The human microfibrillar-associated protein 4 (MFAP4) is located to extracellular matrix fibers and 
plays a role in disease-related tissue remodeling. Previously, we identified MFAP4 as a serum biomarker candidate 
for hepatic fibrosis and cirrhosis in hepatitis C patients. The aim of the present study was to elucidate the potential 
of MFAP4 as biomarker for hepatic fibrosis with a focus on the differentiation of no to moderate (F0–F2) and severe 
fibrosis stages and cirrhosis (F3 and F4, Desmet-Scheuer scoring system).
Methods: MFAP4 levels were measured using an AlphaLISA immunoassay in a retrospective study including n = 542 
hepatitis C patients. We applied a univariate logistic regression model based on MFAP4 serum levels and furthermore 
derived a multivariate model including also age and gender. Youden-optimal cutoffs for binary classification were deter-
mined for both models without restrictions and considering a lower limit of 80 % sensitivity (correct classification of F3 
and F4), respectively. To assess the generalization error, leave-one-out cross validation (LOOCV) was performed.
Results: MFAP4 levels were shown to differ between no to moderate fibrosis stages F0–F2 and severe stages (F3 and 
F4) with high statistical significance (t test on log scale, p value <2.2·10−16). In the LOOCV, the univariate classification 
resulted in 85.8 % sensitivity and 54.9 % specificity while the multivariate model yielded 81.3 % sensitivity and 61.5 % 
specificity (restricted approaches).
Conclusions: We confirmed the applicability of MFAP4 as a novel serum biomarker for assessment of hepatic fibrosis 
and identification of high-risk patients with severe fibrosis stages in hepatitis C. The combination of MFAP4 with exist-
ing tests might lead to a more accurate non-invasive diagnosis of hepatic fibrosis and allow a cost-effective disease 
management in the era of new direct acting antivirals.
Keywords: Hepatic fibrosis, Cirrhosis, Microfibrillar-associated protein 4, Serum biomarker, Hepatitis C, Direct acting 
antivirals
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Background
The hepatitis C virus (HCV) infection represents one of 
the main causes of chronic liver diseases worldwide [1]. 
Estimations of global HCV prevalence range from >185 
million people with anti-HCV in 2005 (corresponding 
to 2.8  % of the population) [2] to 160 million people in 
2013 [1]. Recently published data suggests that the global 
prevalence of viraemic HCV infections was 1.1 % in 2013 
corresponding to 80 (64–103) million persons; with 
approximately 3.8 million viraemic infections in Western 
and Central Europe and 2.8 million infections in North 
America [3]. In recent years the treatment regimens for 
hepatitis C have changed dramatically. The new direct 
acting antivirals (DAAs) showed a higher efficiency and 
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less side effects than previous interferon-based thera-
pies thereby offering new treatment opportunities [4, 
5]. Dependent on the HCV genotype, sustained viral 
response (SVR) rates of 40–80 % were reached with old 
treatment regimens whereas therapies with new DAAs 
promise SVR rates above 90 % [5]. On the other hand the 
extreme costs associated with the new drugs may over-
burden the healthcare systems which makes it necessary 
to first identify those patients which are in greatest need 
of therapy [6, 7].
The disease progression of hepatitis C infection is char-
acterized by the development of hepatic fibrosis, but its 
course is highly variable. It ranges from minimal histolog-
ical impairments to extensive fibrosis and cirrhosis with 
or without development of hepatocellular carcinoma 
(HCC) [8]. Currently, the European Association for the 
Study of the Liver (EASL) recommendations in 2015 on 
treatment of hepatitis C suggest prioritized treatment of 
patients with fibrosis stage F3 and F4 (METAVIR) while 
treatment is justified for stage F2. For stages F0 and F1 
the timing of the therapy may be individualized [5]. Up 
to now, a liver biopsy is considered the gold standard for 
assessment of hepatic fibrosis although the procedure is 
invasive and carries a significant rate of complications, 
especially in patients with coagulation disorders (e.g. 
patients with advanced cirrhosis) [9]. Moreover, liver 
biopsy is prone to inter-observer-variability and sampling 
error as only a small fraction of the liver is analyzed [10]. 
To reduce the need of biopsy, many efforts were made 
in the last 15 years to develop non-invasive methods for 
assessment of hepatic fibrosis and imaging modalities 
to measure liver stiffness by transient elastography (TE) 
were developed (FibroScan, Echosens, Paris, France) 
[11]. Other tests such as FibroTest, also known as Fibro-
Sure [12] or the AST to platelet ratio index (APRI) [13] 
combine several serum parameters in scores to assess 
the stage of hepatic fibrosis. These diverse non-invasive 
tests have been extensively investigated in viral hepatitis 
[14] and showed an improved performance when used 
in combination [15]. However, several confounders must 
be taken in consideration for interpreting these tests and 
complicate a valid fibrosis assessment. One example is 
the commonly used FibroTest score, which is calculated 
using a blood test combining six serum markers with the 
age and gender of the patients. It is known that ribavirin 
therapy can induce hemolysis leading to decreased lev-
els of haptoglobin, which is one of the six serum mark-
ers, therefore representing potential bias for the test. 
Furthermore, transient elastography is frequently not 
interpretable, especially in obese patients or those with 
ascites in decompensated cirrhosis [15]. This illustrates 
that improvement of existing tests is still necessary to 
ensure the valid diagnosis of hepatic fibrosis, which is 
essential for the therapeutic management of the hepatitis 
C infection.
To identify new biomarker candidates for hepatic fibro-
sis, we previously used a proteomics approach to analyze 
microdissected cirrhotic septae and liver parenchyma 
cells [16]. We detected an elevated abundance of extracel-
lular human MFAP4 in the cirrhotic septae and recently 
confirmed the elevated expression of MFAP4 in hepatic 
fibrosis investigating tissue samples from a larger patient 
cohort [17]. The quantitative analysis of MFAP4 serum 
levels in hepatitis C patients by ELISA already demon-
strated its applicability as a blood-based biomarker for 
non-invasive assessment of liver fibrosis. These results 
indicated a promising diagnostic accuracy for the predic-
tion of non-diseased liver versus cirrhosis [16]. However, 
the statistical power was not sufficient to allow an accu-
rate discrimination of no to moderate stages of hepatic 
fibrosis (F0–F2) from severe fibrosis and cirrhosis (F3 
and F4). The aim of the present study was to assess the 
applicability of MFAP4 as a serum biomarker for hepatic 
fibrosis for the discrimination of fibrosis stages F0–F2 
from fibrosis stages F3 and F4 investigating a large cohort 
of hepatitis C patients (n  =  542). The performance of 
MFAP4 in this differentiation is of particular relevance as 
patients with severe fibrosis should immediately receive 
treatment with new direct acting antiviral drugs.
Methods
Clinical cohort
Serum samples collected by the German network of 
Excellence for Viral Hepatitis (HepNet, http://www.
kompetenznetz-hepatitis.de) were used for the analy-
sis of serum MFAP4 in patients with different stages of 
hepatic fibrosis. The study was approved by the local 
ethics committee and the procedure and the use of a 
part of the biopsy for this study were explained to the 
patients. All patients gave informed consent. The sam-
ples were collected at different sites using a standardized 
protocol reducing bias by inhomogeneous pre-analytical 
sample treatment. Patients with HCV RNA detectable 
by PCR who had undergone liver biopsy between 2001 
and 2006 were included in the study. The resulting clini-
cal cohort consisted of 555 samples in total and the col-
lected patient information included covariates such as 
age, gender, HCV genotype or presence of co-morbid 
HCC. For the present analysis, we only considered 
patients with chronic HCV infection and available val-
ues for MFAP4 level, fibrosis, age and gender resulting 
in a sample size of n = 542. A descriptive analysis of the 
available relevant covariates can be found in Table 1 and 
Additional file 1.
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Histologic staging
Biopsies were staged blindly according to the Desmet-
Scheuer scoring [18] system by one pathologist with a 
specialization in liver pathology. Every biopsy specimen 
was staged on a scale of fibrosis F0 to F4: F0—no fibro-
sis; F1—enlarged, fibrotic portal tracts; F2—periportal 
fibrosis or portal–portal septa, but intact architecture; 
F3—fibrosis with architectural distortion, but no obvious 
cirrhosis; and F4—probable or definite cirrhosis.
Sampling and laboratory measurements
MFAP4 was measured by AlphaLISA technique (Perki-
nElmer) as described in detail before [19]. Briefly, two 
monoclonal anti-MFAP4 antibodies (HG-HYB 7–14 
and HG-HYB 7–18) that were generated using MFAP4-
deficient mice [20] were used as acceptor and donor anti-
bodies, respectively. Measurements were performed in 
384 well format and all sera were tested in duplicates in 
a 1:100 dilution. When being measured in serum samples 
1 U/ml MFAP4 corresponds to 38 ng/ml of MFAP4.
Analysis of variance
We applied a log2 transformation to MFAP4 measure-
ments in order to reduce the skewness and obtain a 
more symmetrical distribution. Based on the assessment 
of q–q plots normality could be assumed for the trans-
formed data (data not shown). The association between 
fibrosis stage and observed MFAP4 levels was initially 
assessed by a two-group comparison of no to moderate 
fibrosis (F0–F2) vs. severe fibrosis and cirrhosis (F3, F4) 
by Student’s t test. A one-sided hypothesis was tested to 
reflect and eventually validate the assumption of higher 
values in severe fibrosis stages and cirrhosis. Equal vari-
ances were assumed after the log transformation. To 
achieve a comprehensive evaluation, we also analyzed the 
fibrosis stages individually, using ANOVA to test for dif-
ferences in mean MFAP4 levels of the five fibrosis stages. 
Afterwards, Tukey’s‚ honest significant difference (HSD) 
method was used for pairwise comparisons between 
the individual stages in case of a significant result of the 
ANOVA. The chosen significance level in this work was 
0.05.
Logistic regression and diagnostic characteristics
Different classification models based on logistic regres-
sion (details below) were derived to distinguish patients 
with no to moderate fibrosis stages (F0–F2) from patients 
with severe fibrosis and cirrhosis (F3, F4). The discrimi-
native power of the resulting models was assessed by 
means of the AUC value (area under the receiver operat-
ing characteristics (ROC) curve) and the corresponding 
95 % confidence interval (CI) based on DeLong’s method. 
We considered the group of stages F3 and F4 as cases, 
and in the following analyses sensitivity is defined as 
the (true) probability of classifying samples from F3 and 
F4 correctly, while specificity is the (true) probability of 
assigning a sample of stages F0–F2 to the correct group.
The performance of the univariate model yuni solely 
based on MFAP4 measurements was compared to the 
performance of a multivariate model ymulti that addi-
tionally accounts for age and gender of the patients. For 
these additional covariates, previous studies have shown 
an association with MFAP4 serum levels [20, 21]. After 
fitting the respective model, a cutoff was determined in 
Table 1 Patient cohorts characteristics, subdivided by fibrosis stage
a Hepatic fibrosis was assessed by examination of liver biopsies by an experienced pathologist and staged according to Desmet-Scheuer scoring system
b For the age, the mean value per fibrosis stage is reported along with the corresponding standard deviation
c For gender and HCV genotype absolute frequencies are given
Fibrosis stagea F0 F1 F2 F3 F4 All stages
Ageb
Mean age SD 43.75 ± 12.11 44.83 ± 12.64 51.24 ± 12.04 57.10 ± 10.49 57.33 ± 11.31 49.30 ± 13.08
Genderc
Women 52 85 66 36 28 267
Men 45 91 69 31 39 275
Number of patients 97 176 135 67 67 542
HCV genotypec
1 70 126 100 50 43 390
2 2 12 1 1 3 19
3 11 25 12 5 7 60
4 0 4 4 1 0 9
Other 0 1 0 0 0 1
NA 14 8 18 10 14 64
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order to define a binary classification rule for the assign-
ment of samples to the group of either F0–F2 or F3 and 
F4. Generally, we used Youden’s criterion for the cutoff 
selection, which maximizes the sum of sensitivity and 
specificity. Confidence intervals for sensitivity and speci-
ficity are based on the assumption of underlying bino-
mial distributions and represent the 95  % confidence 
level.
In the target clinical application, the future classifier 
will affect the identification of ‘high-risk’ patients with 
severe fibrosis and cirrhosis (F3, F4). Thus, a lower limit 
for sensitivity (correct classification of F3 and F4) was 
considered, which translated into the analysis of a par-
tial AUC (pAUC): The optimized cutoff was determined 
in a predefined range of sensitivity (0.80–1.00), using 
Youden’s criterion as for the traditional approach. We 
list sensitivity and specificity for Youden-optimal cut-
offs resulting from the unrestricted analysis as well as 
for a minimum sensitivity value of 0.8. Note that these 
diagnostic values are prone to overoptimism, owing to 
the optimization process. In order to assess the gener-
alization error, leave-one-out cross validation (LOOCV) 
was performed for each of the modelling approaches 
(restricted/unrestricted  ×  univariate/multivariate). The 
values of sensitivity and specificity obtained from the 
LOOCV analysis are valid estimates for the true char-
acteristics that the classifier would achieve on future 
independent cohorts. In the leave-one-out cross valida-
tion, the approach of interest (here fit of logistic model 
and choice of classification cutoff) is applied to the data 
set which was reduced by a single sample. The resulting 
model is then used to predict the class assignment (high 
or low fibrosis stage) of the left-out sample. With n being 
the total number of samples, this process is carried out 
n times, leaving out a different sample each time. The 
sensitivity and specificity of the LOOCV procedure are 
given by the proportion of correctly classified samples 
from high and low fibrosis stages, respectively.
Results
Analysis of variance
According to current EASL recommendations we 
focused on the differentiation of no to moderate fibrosis 
stages (F0–F2) and severe fibrosis and cirrhosis (F3, F4) 
by means of (log2) MFAP4 measurements (Fig.  1). We 
observed high statistical significance for this comparison 
(t test: p value <2.2*10−16 assuming equal variances) with 
mean values 3.15 (log2 U/ml) for stages F0–F2 and 4.19 
(log2  U/ml) for stages F3 and F4. In addition, we tested 
for differences in means of the individual fibrosis stages 
by ANOVA and Tukey’s HSD post hoc test. We observed 
statistically significant differences except for compari-
sons of adjacent stages within the classes low and high, 
i.e. stages F0 vs. F1, F1 vs. F2 and F3 vs. F4. All results are 
summarized in Table 2. 
Diagnostic characteristics
To estimate the diagnostic potential of MFAP4 we per-
formed ROC curve analysis and determined the optimal 
cutoffs for the discrimination of fibrosis stages F0–F2 and 
F3 and F4 using two different logistic regression models. 
First, we report the diagnostic characteristics estimated 
on the complete data set: The application of the univari-
ate regression model yuni, with
yielded 73.1  % sensitivity and 75.0  % specificity (AUC 
0.790, Fig. 2). The optimization considering a minimum 
of 80 % sensitivity resulted in a sensitivity of 86.6 % and 
a decreased specificity of 54.9 %. For the univariate mod-
els, these diagnostic values barely decreased in the cross 
validation: The LOOCV resulted in 71.6 % sensitivity and 
75  % specificity for the unrestricted model and 85.8  % 
sensitivity and 54.9  % specificity when a minimum sen-
sitivity of 80 % was considered. All estimated values are 
summarized in Table 3 along with the corresponding CIs. 
The derived multivariate logistic regression model was 
calculated as follows:
where Ifemale is 1 if the sample to be classified is from a 
female patient and 0 otherwise.
The application of the multivariate model resulted in 
88.8 % sensitivity and 63.2 % specificity (AUC 0.831) both 
when estimated without restrictions and when a lower 
limit of 80 % sensitivity was considered (Fig. 2). For the 
multivariate model the LOOCV  resulted in 80.6 % sen-
sitivity when the analysis was unrestricted and 81.3  % 
sensitivity when the lower limit of 80  % sensitivity was 
applied. For both approaches the specificity was 61.5 %. 
A summary of all estimated values is given in Table 3. In 
summary, the AUC increases with the inclusion of the 
previously reported confounders age and gender into the 
logistic model. Notably, the additional area is related to 
an increased sensitivity in the range of lower to medium 
specificity. This is especially beneficial in the given clini-
cal setting, where we focus on high sensitivity to identify 
patients in need of immediate treatment. Comparing the 
diagnostic values for sensitivity and specificity obtained 
from the LOOCV analysis, the restricted multivariate 
classification model also yields the higher Youden index 
than the univariate.
yuni = −5.50+ 1.20 log2MFAP4
ymulti = −7.31+ 1.02 log2 MFAP4 − 0.51Ifemale + 0.05 age,
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Discussion
According to the current EASL recommendations, the 
stage of hepatic fibrosis is a key factor to identify patients 
who should receive immediate treatment with new DAAs 
[5]. Hence, the importance of identification of patients 
with advanced fibrosis stages is obvious. Several non-
invasive tests have been developed and each has spe-
cific advantages and disadvantages [22]. Measuring liver 
Fig. 1 Two group comparison for the differentiation of no to moderate (F0–F2) and severe (F3, F4) fibrosis stages. Upper and lower bounds of boxes 
represent the first and third quartile per group, whiskers extend to the most extreme data point which is no more than 1.5 times the interquartile 
range from the box. Circles represent individual data points. Solid grey boxes represent the summarized two experimental groups tested for statistical 
significance by Student’s t test (p value < 2.2·10−16), while the white boxes represent the individual fibrosis stages F0–F4 (Desmet-Scheuer score). For 
reasons of clarity, the box plots for the combined groups (0–2 vs. 3–4) do not display the individual data points as the box plots for the individual 
groups
Table 2 Results of the pairwise comparisons of  individual 
hepatic fibrosis stages with  respect to  log2 MFAP4 values 
after significant ANOVA result
a Pairwise comparison between individual fibrosis stages
b Estimated difference between true mean values of individual groups (log2 U/
ml)
c Upper respectively lower bound of the 95 % confidence interval of difference 
(log2 U/ml)
d Adjusted p value according to Tukey’s‚ honest significant difference’ post hoc 
test
Compari-
sona
Differenceb Lower  
boundc
Upper  
boundc
p valued
F1–F0 0.1924 −0.1114 0.4962 0.4144
F2–F0 0.4386 0.1188 0.7584 0.0018
F3–F0 1.1168 0.7351 1.4984 3.43E−10
F4–F0 1.4277 1.0461 1.8092 3.43E−10
F2–F1 0.2462 −0.0287 0.5211 0.1036
F3–F1 0.9244 0.5796 1.2693 3.51E−10
F4–F1 1.2353 0.8903 1.5802 3.43E−10
F3–F2 0.6782 0.3191 1.0373 3.280E−6
F4–F2 0.9891 0.6300 1.3482 3.45E−10
F4–F3 0.3109 −0.1042 0.7260 0.2438
Fig. 2 ROC curves based on univariate logistic regression model con-
sidering solely MFAP4 serum concentrations (grey line) and multivari-
ate model considering also age and gender (black line), respectively. 
MFAP4 serum concentrations were measured in patients with differ-
ent stages of hepatic fibrosis (F0–F4 according to Desmet-Scheuer-
scoring system). The ROC curves represent the differentiation of mild 
to moderate (F0–F2) and severe fibrosis and cirrhosis stages (F3, F4). 
AUC values represent the area under the respective curves, values in 
brackets represent the 95 % confidence intervals. The given cutoffs 
are Youden-optimized with no restriction and within a sensitivity 
range of 0.8–1 indicated by the horizontal line on top of the graph, 
respectively. As the ROC curves represent the complete data set, cor-
responding diagnostic characteristics indicated at the optimal cutoffs 
are prone to overoptimism. Please refer to text for LOOCV results
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stiffness by TE is widely used and performs well in iden-
tification of cirrhosis. However, TE has been shown to 
be frequently not interpretable [15]. Furthermore, TE is 
generally limited by user experience [23], and requires a 
specific device. Serum tests are either based on indirect 
or direct markers. Indirect markers are parameters which 
are assessed in routine diagnostics and are combined 
into specific scores, some of which are protected by their 
commercial providers and therefore only limited avail-
able (e.g. FibroTest, Hepascore [24], Fibrometer [25]). 
Indirect markers are usually not disease specific and 
might produce false positive results due to comorbidities, 
e.g. in acute hepatitis if aspartate aminotransferase levels 
are included in the scoring algorithms (e.g. APRI, Fibro-
meter). Direct markers, such as TIMP metallopeptidase 
inhibitor 1 (TIMP1), hyaluronate [26] or metalloprotein-
ases (MMP1, MMP3; e.g. FibroSpectII [27], ELF score 
[28]) reflect the processes of ECM remodeling, which 
take place in the liver. Therefore, direct markers seem to 
consolidate the rationale of a given test, when they are 
combined with indirect markers. Although the combi-
nation of several blood tests has been demonstrated to 
enhance the diagnostic accuracy [15, 29, 30], an ideal 
test does not yet exist and further improvement of the 
diagnostic tools is still necessary. In the present study, 
we examined the potential of MFAP4 to serve as a new 
serum biomarker for the assessment of hepatic fibrosis. 
In line with current treatment guidelines we emphasized 
the differentiation of patients with no to mild fibrosis 
(F0–F2) from severe fibrosis and cirrhosis (F3, F4).
MFAP4 is located in the extracellular matrix (ECM) 
and expressed in association with ECM fibers includ-
ing elastic fibers in the entire body [19]. It also has been 
suggested to be involved in elastic fiber formation [31, 
32]. Although only little is known about its molecular 
function, the relevance of MFAP4 is well-established for 
diseases associated with remodeling of the ECM such as 
vascular stenosis [33] and liver fibrosis [16, 17]. We dem-
onstrated that MFAP4 plasma levels correlate with TE 
measurements and are significantly increased in patients 
with chronic HCV infection [21]. Moreover, MFAP4 
has been shown to be involved in respiratory diseases 
[34–37]. However, recent data suggests that MFAP4 is 
not elevated in sera of patients with idiopathic pulmo-
nary fibrosis (IPF) [38]. To assess MFAP4 serum levels 
for diagnostic purposes we established and further devel-
oped an immunoassay and examined the characteris-
tics of MFAP4 in this context. MFAP4 was shown to be 
robust against variations in sample handling and stor-
age conditions including repeated freeze and thaw cycles 
indicating ideal properties for usage in a clinical setting 
[20]. Several confounders that influence MFAP4 serum 
levels, such as age, sex, waist to hip ratio and smoking 
habits were already determined [20]. Several known con-
founders had not been acquired for the clinical cohort 
we used in the present retrospective study except for age 
and gender. For these, our results confirmed significant 
influence on (log2) MFAP4 serum levels in a multivariate 
logistic regression model. Furthermore, a lack of knowl-
edge about patient’s comorbidities known to be capable 
of influencing MFAP4 serum levels has the potential to 
bias our results. Previously, we identified various car-
diovascular conditions as well as COPD to be corre-
lated with elevated MFAP4 serum levels [19, 35]. Yet, in 
a recent study only congestive heart failure was found to 
be associated with significantly increased MFAP4 plasma 
levels [21]. In addition, the cohort used in this study was 
not homogeneous regarding previous treatment. Parts 
of the cohort received IFN-based therapy with or with-
out combination with ribavirin. However, the data were 
Table 3 Sensitivity and specificity of the univariate and multivariate classification, respectively
a A multivariate logistic regression model considering age and gender besides MFAP4 serum levels was derived and the respective Youden optimal cutoffs were 
determined
b Cutoff optimization was restricted to a minimum sensitivity of 80 % accounting for the importance of the identification of high fibrosis stages
c Sensitivity was defined as probability of classifying stages F3 and F4 correctly
d Specificity was defined as probability of classifying stages F0 to F2 correctly
e As sensitivity and specificity values are prone to overoptimism in the analysis of the complete data set leave-one-out cross validation was performed to obtain 
unbiased estimates
Multivariate modela Univariate model
Unrestricted Lower limit of 80 % 
sensitivityb,c
Unrestricted Lower limit of 80 % 
sensitivityb,c
Sensitivityc estimate [95 % CI] 88.8 % [82.2 %; 93.6 %] 88.8 % [82.2 %; 93.6 %] 73.1 % [64.8 %; 80.4 %] 86.6 % [79.6 %; 91.8 %]
Specificityd estimate [95 % CI] 63.2 % [58.4 %; 67.9 %] 63.2 % [58.4 %; 67.9 %] 75.0 % [70.5 %; 79.1 %] 54.9 % [49.9 %; 59.8 %]
Leave-one-out cross validatione
Sensitivityc estimate [95 % CI] 80.6 % [72.9 %; 86.9 %] 81.3 % [73.7 %; 87.5 %] 71.6 % [63.2 %; 79.1 %] 85.8 % [78.7 %; 91.2 %]
Specificityd estimate [95 % CI] 61.5 % [56.6 %; 66.3 %] 61.5 % [56.6 %; 66.3 %] 75.0 % [70.5 %; 79.1 %] 54.9 % [49.9 %; 59.8 %]
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incomplete regarding therapeutic measures. In future 
prospective studies, the complete set of known con-
founders needs to be acquired and considered in a clas-
sification model for a thorough analysis. In consequence, 
we expect an improved model with increased diagnostic 
accuracy.
The established non-invasive tests for assessment of 
liver fibrosis have been extensively evaluated in the past 
[39, 40] and prospective studies allowing assessment of 
more relevant parameters were performed. Most estab-
lished tests show a relatively good performance in predic-
tion of cirrhosis (F4) but perform less well in diagnosis 
of severe fibrosis (F3). However, the accurate diagnosis 
of severe fibrosis and cirrhosis is the key requirement 
for non-invasive tests right now [5]. For prediction of 
fibrosis stages F3 and F4 (METAVIR) FibroScan showed 
an AUC of 0.75 (sensitivity 89.7 %, specificity 32.2 %) in 
a cohort of HCV patients [41]. Recently, the most com-
mon blood tests were evaluated for diagnosis of severe 
fibrosis in a prospective study showing AUCs of 0.82 for 
Fibrometer and Hepascore, respectively. APRI showed 
an AUC of 0.76 and the ELF score yielded an AUC of 
0.78 [15]. Notably, we achieved comparable values using 
both either the univariate model (85.8  % sensitivity and 
54.9  % specificity, AUC 0.79) or the multivariate model 
(81.3  % sensitivity and 61.5  % specificity, AUC 0.83) for 
diagnosis of fibrosis stages F3 and F4 in a more heteroge-
neous cohort. As these estimates are obtained from the 
LOOCV these estimates are basically unbiased. How-
ever, none of the established non-invasive tests could be 
applied to our same samples set, hence only an indirect 
comparison of the tests was possible and ultimate con-
clusions are still pending.
As patients suffering from severe fibrosis and cirrho-
sis (F3, F4) need to receive immediate treatment, which 
however is unfortunately often limited by the high cost 
associated with the DAAs, we considered the correct 
diagnosis of these patients to be of highest relevance 
in a clinical setting. In the class of lower fibrosis stages, 
one should further distinguish between misclassification 
of stages F0–F1 and stage F2, as immediate treatment is 
also justified for the latter one, but less important than 
for F3 and F4. A false diagnosis of no to moderate (F0–
F2) might lead to immediate treatment, which is gener-
ally beneficial for the patients but involves high expenses. 
Therefore, we used an alternative approach, which 
focuses on the reliable diagnosis of patients with fibro-
sis stages F3 and F4 by calculating the optimized cut-
offs for a minimum sensitivity (correct diagnosis stages 
F3 and F4) of 80 %. To our opinion, this is a reasonable 
choice for a minimum sensitivity and still yields accept-
able values for specificity. For this lower bound the opti-
mal classifier resulted in 85.8  % sensitivity and 54.9  % 
specificity for the univariate model. 81.3 % sensitivity and 
61.5 % specificity were reached applying the multivariate 
model (Table 3, LOO cross validated values). These val-
ues represent the correct identification of 85.8 and 81.3 % 
of patients in the greatest need of immediate therapy. 
While for the multivariate model the sensitivity is slightly 
decreased compared to the univariate one, the specificity 
increased (61.5 % compared to 54.9 %). Here, decreased 
specificity means that patients with lower fibrosis stages 
(F0–F2) are misclassified, thus, they are suggested for 
DAA treatment. As immediate treatment is justified for 
F2 patients, their misclassification increases overall treat-
ment expenses but still is in line with EASL recommen-
dations. We therefore assessed the misclassification rates 
for the lower fibrosis stages separately and F2 turned 
out to have the highest misclassification rate of about 
50 %, which qualifies the rather low values for specificity 
reported above.
Conclusions
We were able to demonstrate the applicability of 
MFAP4 as a serum biomarker for hepatic fibrosis in a 
large cohort of hepatitis C patients. Both, a univariate 
logistic regression model considering solely MFAP4 
serum levels as well as a multivariate model taking 
into account also age and gender were applied. Albeit 
a great heterogeneity of the analyzed cohort must be 
assumed, both models resulted in sensitivity and speci-
ficity estimates comparable with existing tests. We 
showed that our models facilitate the reliable identi-
fication of patients with severe fibrosis stages (F3 and 
F4) reflecting the need of prioritized treatment of these 
patients according to the current EASL recommenda-
tions. In consequence, MFAP4 may prospectively help 
improving the cost-effective management of the hepa-
titis C-infection and the disease specific complications, 
considering the necessity of immediate therapy of high-
risk patients.
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